Many patients with newly diagnosed multiple myeloma (MM), non-Hodgkin lymphoma/diffuse large B-cell lymphoma (NHL-DLBCL), and chronic lymphocytic leukemia (CLL) have low vitamin D levels, according to a study published in The Journal of International Medical Research.
Researchers recruited 103 patients (37 with MM, 32 with CLL, and 34 with NHL-DLBCL) and quantified their serum levels of vitamin D using enzyme-linked immunosorbent assay.
Following analysis, the researchers observed suboptimal serum vitamin D levels (<30 ng/mL) in all study participants. They noted that in 14 patients, serum vitamin D levels were between 20 ng/mL and 30 ng/mL, while all other patients had vitamin D deficiency (<20 ng/mL). Moreover, they observed severe vitamin D deficiency in more than 30% of patients with NHL-DLBCL, 28.1% of patients with CLL, and 81% of patients with MM.
“Despite these unidirectional results, the inclusion of three cohorts of patients was an advantage, enabling comparisons between the three groups. It was also a disadvantage because of the different nature of these three diseases,” the researchers concluded.
They added that the study was limited “because of the low number of patients included in each group and the lack of a control group of healthy individuals. Our results warrant further evaluation in other prospective studies, ideally using a large number of patients and a matched healthy control group. Because the prevalence of vitamin D deficiency appears to be high in different hematological malignancies, further studies evaluating the impact of maintaining adequate vitamin D levels on treatment and survival as week as prevention of secondary neoplasms is needed.”